PONTE
VEDRA, Fla., Feb. 6, 2023
/PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD),
a biopharmaceutical company focused on developing tecarfarin, a
clinical-stage novel cardiorenal therapy with orphan drug and Fast
Track designations, today announced that Chairman and Chief
Executive Officer, Quang Pham, is
available for one-on-one meetings at the BIO CEO & Investor
Conference taking place at the New York Marriott Marquis Times
Square on February 6-8, 2023.
Meetings with conference attendees can be scheduled through the
BIO One-on-One Partnering system:
https://www.bio.org/events/bio-ceo-investor-digital-conference/partnering,
or by emailing our corporate contacts using the information
provided at the end of this press release.
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal Therapeutics is focused on developing tecarfarin, a
novel cardiorenal therapy with orphan drug and Fast Track
designations for the prevention of systemic thromboembolism (blood
clots) of cardiac origin in patients with end-stage renal disease,
or ESRD, and atrial fibrillation (irregular heartbeat), or AFib.
Tecarfarin is a Vitamin K antagonist oral anticoagulant designed to
target a different pathway than the most commonly prescribed drugs
used in the treatment of thrombosis and AFib. Tecarfarin has been
evaluated in eleven human clinical trials and more than 1,000
individuals. In Phase 1, Phase 2 and Phase 2/3 clinical trials,
tecarfarin has generally been well-tolerated in both healthy adult
subjects and patients with chronic kidney disease. For more
information, please visit: www.cadrenal.com.
For more information, please contact:
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com
Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700,
CVKD@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-to-participate-in-the-2023-bio-ceo--investor-conference-301738951.html
SOURCE Cadrenal Therapeutics, Inc.